Kristi McIntyre is an Oncology physician affiliated with Texas Health Dallas. OpenAlex indexes 79 publications with 6,780 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.1%PD-1 inhibitor23.9%Pembrolizumab100%Part B, office-administered≥22 patientsPlatinum-based Drug14.7%Oxaliplatin98%Carboplatin2%Part B, office-administered≥17 patients+ 7 more classes in this area
Blood & clotting
25.3%Parenteral Iron Replacement13%Iron sucrose100%Part B, office-administered≥26 patientsErythropoiesis-stimulating Agent12.2%Darbepoetin alfa100%Part B, office-administered≥19 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.7%Other antiemetics18.8%Fosaprepitant100%Part B, office-administered≥39 patientsSerotonin-3 Receptor Antagonist2.7%Palonosetron hcl56%Granisetron hydrochloride42%Ondansetron Odt1%Ondansetron Hcl1%Part D + Part B<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Satyam Sarma, MD
Texas Health Dallas
Khoan Vu, MD
Texas Health Dallas
Salman Bhai, MD
Texas Health Dallas
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”